Product Update

Gensco® Pharma Announces RizaFilm® Commercialization Update in the United States

Gensco® Pharma, a specialty pharmaceutical company, in partnership with IntelGenx is announcing the anticipated launch of RizaFilm® for Q1-2024. RizaFilm® is based on IntelGenx’s proprietary VersaFilm® technology and is patent protected until 2034. As the NDA holder, Gensco® will begin commercialization of the 10mg Film and will continue to fund the expanded indications for the 5mg Pediatric dose.

RizaFilm® is a film formulation of rizatriptan and the only oral dissolvable film available for the treatment of acute migraines. RizaFilm® has ease of convenience and does not require a drink for swallowing, thus allowing for rapid administration and relief from migraine related pain and nausea.

Now Available Through Federal Supply Schedule (FSS)

Now Available Through Federal Supply Schedule (FSS)

Contract #V797D-70219 The Only FDA-Approved Prescription Hydrogel and 4% Lidocaine HCl for Pain Associated with Wound Healing and Vasculitis FDA Approved #K092086 Astero®, manufactured by Gensco Pharma, is now available through the Federal Supply Schedule. Astero®...
Medicare (CGDP) Gap Announcement

Medicare (CGDP) Gap Announcement

Gensco Pharma Announces Additions to 2017 CGDP on CMS Gensco products will be available to MEDICARE patients in 2017